samedan logo
 
 
spacer
home > pmps > spring 2021 > dose counting for metered-dose inhalers – a real patient need
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dose Counting for Metered-Dose Inhalers – A Real Patient Need

Asthma and chronic obstructive pulmonary disease (COPD) are responsible for millions of deaths every year. Controlling and monitoring the treatment for these chronic lung disorders is not only required to reduce healthcare costs related to hospitalisations, but a real patient need. A reliable system to support the correct and on-time use of inhalers, without changing the way of using them or adding any steps to their routine, is vital for sufferers.

The majority of marketed metered-dose inhalers (MDIs) offer no practical way for patients or doctors to know how many doses are left in their inhaler – which is especially pertinent in case of emergency. Furthermore, there is a collective requirement to track adherence or compliance to medication. To address these requirements, the FDA published guidance to integrate dose-counting mechanisms into MDI drug products. As per the guidelines, devices should offer either clear numeric counting mechanisms or indication functions – with a colour code function, for example – to ensure the correct number of doses is displayed to patients (1-2). The guidance also encourages drug manufacturers to update existing devices.

H&T Presspart, as the leading supplier of respiratory drug delivery components, offers a range of dose counters and dose indicator solutions to meet the needs of the metered-dose inhaler market and address the transition towards end of life indication.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
H&T Presspart specialises in industrialising drug delivery devices and components. The products that the company offers its pharmaceutical clients include medical devices, metered-dose inhaler components, and a comprehensive range of dose counting technologies. The company has 50 years’ experience and a worldwide reputation for competence, quality, and innovation in the pharmaceutical sector. H&T Presspart’s Inhalation Product Technology Centre supports its customers through new inhalation product developments and strategic initiatives. H&T Presspart, part of the Heitkamp and Thumann Group, has three European manufacturing sites, in Germany, Spain, and the UK, with sales offices in China, India, Singapore, South America, and the US.
spacer
H&T Presspart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement